ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements with these filters
Choksi Laboratories schedules a 14 November 2026 board meeting to consider unaudited standalone half-yearly results for September 2026. Trading window closes from 1 October until 16 November 2026.
Choksi Laboratories received the USFDA Establishment Inspection Report for its Indore central laboratory, closing the August 2026 inspection. No monetary penalty or fine is mentioned.
Choksi Laboratories' proposed convertible warrants issue was rejected at its EGM on October 17, 2026. The company requests BSE to close the in-principle approval application.
Choksi Laboratories' EGM on 17 Oct 2026 rejected the special resolution to allot convertible warrants to promoters. 99.46% of votes polled were against, blocking the capital raise.
Choksi Laboratories held an EGM regarding the issuance of convertible warrants on a preferential basis. The promoters and proposed allottees abstained from voting on the resolution.
Choksi Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Choksi Laboratories Ltd has scheduled an EGM for October 17, 2026, to seek shareholder approval for issuing 3.50 lakh convertible warrants at ₹177 per warrant.
Choksi Laboratories board approved a preferential issue of 3.5 lakh warrants to promoters at Rs 177 per warrant, totaling Rs 6.195 Crore.
Choksi Laboratories filed proceedings of its 33rd AGM held on 18 September 2026. Directors Sunil Choksi and Himika Choksi were re-appointed as Whole-Time Directors.
Choksi Laboratories announced a Board meeting on September 19, 2026, to discuss a proposal for raising funds through equity or convertible securities.
Choksi Laboratories Limited has dispatched letters to shareholders with unregistered email addresses. The communication provides access details for the FY 2025-26 Annual Report and AGM notice.
Choksi Laboratories has submitted its 33rd Annual Report for the financial year 2025-26. The report and the notice of the upcoming AGM are now available.
Choksi Laboratories Limited has issued the notice for its 33rd Annual General Meeting, scheduled to be held on September 18, 2026, through video conferencing.
Choksi Laboratories reported that the USFDA inspected its central laboratory in Indore. The inspection concluded with four observations, which the company is currently addressing.
Choksi Laboratories has reappointed M/s Tanmay V. Rajurkar & Co. as the company's internal auditor for the financial year 2026-27.
Choksi Laboratories Ltd has re-appointed Ms. Himika Choksi as Whole Time Director for a five-year term effective from April 1, 2027, subject to shareholder approval.
Choksi Laboratories Ltd reported revenue from operations of ₹12.1 Cr (+8.0% YoY) and net profit of ₹0.6 Cr (+50.0% YoY) for Q1 FY27.
Choksi Laboratories has scheduled a Board Meeting for August 13, 2026, to consider unaudited financial results for the quarter ended June 30, 2026.
Choksi Laboratories Limited has changed its Registrar and Share Transfer Agent to Ankit Consultancy Private Limited, effective August 03, 2026. This is a routine administrative update.
Choksi Laboratories Limited filed its shareholding pattern as of 30 June 2026. The filing details promoter and various shareholder categories without monetary transaction.
Choksi Laboratories submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report notes minor past filing delays and current regulatory compliance.
Choksi Laboratories Ltd reported revenue from operations of ₹12.8 Cr (+12.3% YoY) and net profit of ₹1 Cr (+11.1% YoY) for Q4 FY26.
Choksi Laboratories reported annual revenue of ₹46.22 Crore for FY26. Net profit for the year reached ₹1.96 Crore, indicating stable operational performance for investors.
Choksi Laboratories appointed Mrs. Stela Choksi as CFO following Mr. Vyangesh Choksi's resignation. The transition occurred on May 18, 2026, ensuring leadership continuity.
Choksi Laboratories appointed Mrs. Stela Choksi as Chief Financial Officer. This leadership change strengthens executive management and supports regulatory compliance for the listed entity.
Mr. Vyangesh Choksi resigned as Chief Financial Officer of Choksi Laboratories, effective May 18, 2026. He remains the company's Whole Time Director.
Choksi Laboratories approved appointing Mrs. Stela Choksi as CFO following Mr. Vyangesh Choksi's resignation. The board also approved a car purchase and RTA change.
Choksi Laboratories scheduled a board meeting on May 25, 2026, to approve audited financial results for fiscal 2026. Trading window remains closed until 48 hours post-declaration.
Choksi Laboratories scheduled a board meeting for May 18, 2026, to discuss vehicle financing and RTA changes. Investors should monitor outcomes regarding CFO appointments.